Iopromide (Ultravist, BAY86-4877)
Sponsors
Bayer
Conditions
AngiocardiographyAngiographyContrast Enhanced X-ray Based ExaminationContrast MediumDiagnostic ImagingMultidetector Computed Tomography
Unknown Phase
The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)
CompletedNCT01206257
Start: 2010-08-31End: 2011-09-30Updated: 2013-06-11
Observational Study of Ultravist in Patients Requiring CECT
CompletedNCT01415414
Start: 2011-09-30End: 2013-11-30Updated: 2015-01-21
A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting
CompletedNCT02840903
Start: 2016-07-26End: 2017-10-11Updated: 2018-10-02
Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid
CompletedNCT03622801
Start: 2018-10-12End: 2019-02-14Updated: 2020-02-17
A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions
CompletedNCT05428397
Start: 2022-06-30End: 2022-10-28Updated: 2023-10-10